Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: Insights from a meta-analysis of randomised trials

Open Heart

Volumn 1, Issue 1, 2014, Pages

  Bangalore, Sripal ^a   Singh, Amita ^a   Toklu, Bora ^a   DiNicolantonio, James J ^b   Croce, Kevin ^c   Feit, Frederick ^a   Bhatt, Deepak L ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL;

ADVERSE OUTCOME; ARTICLE; BARE METAL STENT; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CLINICAL OUTCOME; COHORT ANALYSIS; COMBINATION DRUG THERAPY; DEATH; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; DUAL ANTIPLATELET THERAPY; EVIDENCE BASED PRACTICE; HEADACHE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART PALPITATION; HEMATOLOGICAL PARAMETERS; HIGH ON TREATMENT PLATELET REACTIVITY; HUMAN; INCIDENCE; META ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PLATELET REACTIVITY UNIT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESTENOSIS; RISK REDUCTION; SIDE EFFECT; STENT THROMBOSIS; TACHYCARDIA; TARGET LESION REVASCULARIZATION; TARGET VESSEL REVASCULARIZATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 84984614477     PISSN: None     EISSN: 20533624     Source Type: Journal    
DOI: 10.1136/openhrt-2014-000068     Document Type: Article

References (70)

1. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-13.
2. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007;49:1505-16.
3. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-51.
4. Tousoulis D, Briasoulis A, Dhamrait S, et al. Effective platelet inhibition by aspirin and clopidogrel: where are we now? Heart 2009;95:850-8.
5. Aradi D, Komosci A, Vorobcsuk A, et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis. Am Heart J 2010;160:543-51.
6. Angiolillo DJ, Capranzano P, Goto S, et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J 2008;29:2202-11.
7. Liu Y, Shakur Y, Yoshitake M, et al. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 2001;19:369-86.
8. Fujinaga K, Onoda K, Yamamoto K, et al. Locally applied cilostazol suppresses neointimal hyperplasia by inhibiting tenascin-C synthesis and smooth muscle cell proliferation in free artery grafts. J Thorac Cardiovasc Surg 2004;128:357-63.
9. Tsai C-S, Lin F, Chen Y, et al. Cilostazol attenuates MCP-1 and MMP-9 expression in vivo in LPS-administrated balloon-injured rabbit aorta and in vitro in LPS-treated monocytic THP-1 cells. J Cell Biochem 2007;103:54-66.
10. Min P-K, Jung J, Ko Y, et al. Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting. Circ J 2007;71:1685-90.
11. Lee S-W, Park S, Yun S, et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-eluting stenting followed by cilostazol treatment reduces adverse serious cardiac events (DECREASE registry). Am Heart J 2010:284-91.
12. Higgins JP, Green S. Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions version. 500 edn. Oxford: The Cochrane Collaboration, 2008.
13. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-33.
14. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 1999;354:1896-900.
15. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration, 2008. http://www.cochrane-handbook.org (accessed 12 Dec 2013).
16. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
17. Brar SS, ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011;58:1945-54.
18. Gurbel PA, Tantry US. Acceptance of high platelet reactivity as a risk factor: now, what do we do about it? JACC Cardiovasc Interv 2010;3:1008-10.
19. Barker CM, Murray SS, Teirstein PS, et al. Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity. JACC Cardiovasc Interv 2010;3:1001-7.
20. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097-105.
21. Price MJ, Angiolillo DJ, Teirstein PS, et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011;124:1132-7.
22. Michelson AD, Frelinger AL III, Braunwald E, et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009;30:1753-63.
23. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15.
24. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
25. Collet JP, Cuisset T, Range G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100-9.
26. Jang JS, Jin HY, Seo JS, et al. A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation. Cardiology 2012;122:133-43.
27. Sakurai R, Koo BK, Kaneda H, et al. Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials. Int J Cardiol 2013;167:2250-8.
28. Kumbhani DJ, Bhatt DL. Secondary prevention of stroke: can we do better than aspirin? Lancet Neurol 2010;9:942-3.
29. Jeong Y-H, Hwang J, Kim I, et al. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ Cardiovasc Interv 2010;3:17-26.
30. Jeong Y-H. ACCEL-LOADING-ACS - Multicenter randomized trial evaluating efficacy of cilostazol on platelet aggregation, Inflammation, and myonecrosis in ACS patients. TCT-AP 2012.
31. Hwang SJ, Jeong YH, Kim IS, et al. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2010;3:450-9.
32. Jeong YH, Hwang S, Park T, et al. Pharmacodynamic effects of adding cilostazol versus double-dose clopidogrel in patients with acute myocardial infarction during proton pump inhibitor co-administration (ACCEL-PPI). J Am Coll Cardiol 2012;59:A127.
33. Jeong Y-H, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive cilostazol versus high maintenance dose clopidogrel in patients with clopidogrel resistance) randomized study. J Am Coll Cardiol 2009;53:1101-9.
34. Suh J-W, Lee S, Park K, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol 2011;57:280-9.
35. Gao W, Zhang Q, Ge H, et al. Efficacy and safety of triple antiplatelet therapy in obese patients undergoing stent implantation. Angiology 2013;64:554-8.
36. Guan SY, Han YL, Li Y, et al. [Effects of intensive antiplatelet therapy for patients with high on-treatment platelet reactivity after coronary stent implantation]. Zhonghua Xin Xue Guan Bing Za Zhi 2012;40:25-9.
37. Park KW, Kang SH, Park JJ, et al. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-eluting stents & anti-platelet regimen). JACC Cardiovasc Interv 2013;6:932-42.
38. Jeong YH, Park Y, Koh JS, et al. Reappraisal of Pharmacodynamic Effect of Adjunctive Cilostazol and High-dose Clopidogrel in East Asian ACS Patients. TCT-AP. 2014.
39. Jin EZ, Yu L, Li X. Loading effect of 200 mg cilostazol on platelet inhibition in patients undergoing percutaneous coronary intervention. Int Heart J 2012;53:1-4.
40. Kim IS, Jeong YH, Park Y, et al. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. JACC Cardiovasc Interv 2011;4:381-91.
41. Kim J-Y, Lee K, Shin M, et al. Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ J 2007;71:1867-72.
42. Kum DS, Kim M, Paik J, et al. Clinical effects of additional cilostazol administration after drug-eluting stent insertion Korean Circ J 2009;39:21-5.
43. Lee K, Kim J, Yoo B, et al. Cilostazol augments the inhibition of platelet aggregation in clopidogrel low-responders. J Thromb Hemost 2010;8:2577-9.
44. Woo JS, Kim W, Lee S, et al. Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: Results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease(PIANO-2 CKD) randomized study. Am Heart J 2011;162:1018-25.
45. Shim CY, Yoon S, Park S, et al. The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stent implantation. Int J Cardiol 2009;134:351.
46. Youn YJ, Lee JW, Ahn SG, et al. Multicenter randomized trial of 3-month cilostazol use in addition to dual antiplatelet therapy after biolimus-eluting stent implantation for long or multivessel coronary artery disease. Am Heart J 2014;167:241-8 e1.
47. Ahn C, Hong S, Park J, et al. Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. Heart Vessels 2011;26:502-10.
48. Chen Y-d, Lu Y, Jin Z, et al. A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent. Chin Med J 2006;119:360-6.
49. Ahn Y, Jeong M, Jeong J, et al. Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients (CIDES Trial). Circ J 2008;72:35-9.
50. Kim BK, Oh SJ, Yoon SJ, et al. A randomized study assessing the effects of pretreatment with cilostazol on periprocedural myonecrosis after percutaneous coronary intervention. Yonsei Med J 2011;52:717-26.
51. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005;112:2826-32.
52. Lee SW, Park SW, Kim YH, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES trial (A randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients). J Am Coll Cardiol 2008;51:1181-7.
53. Lee SW, Chun KJ, Park SW, et al. Comparison of triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the Declare-Diabetes and Long Trials). Am J Cardiol 2010;105:168-73.
54. Lee SW, Park SW, Kim YH, et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol 2007;100:1103-8.
55. Lee SW, Park SW, Kim YH, et al. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with long coronary lesions) trial. J Am Coll Cardiol 2011;57:1264-70.
56. Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009;157:733-9.
57. Han Y, Su Q, Li Y, et al. The effects of post coronary stenting triple antiplatelet therapies on platelet functions. Chin J Intern Med 2006;45:635-8.
58. Hu T, Ma H, Li H, et al. Efficacy of cilostazol in patients with acute coronary syndrome after percutaneous coronary intervention. Am J Ther 2013;20:151-3.
59. Kim DH, Kim J, Moon S, et al. Effects of long-term triple anti-platelet therapy with low dose cilostazol after drug-eluting stent implantation. Korean J Med 2008;74:368-75.
60. Lee B-K, Lee SW, Park SW, et al. Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation. Am J Cardiol 2007;100:610-14.
61. Kim YH, Park SW, Lee SW, et al. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation 2006;114:2148-53.
62. Kelbaek H, Klovgaard L, Helqvist S, et al. Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting coronary arteries in non-stress/benestent disease) trial. J Am Coll Cardiol 2008;51:2011-16.
63. Baumgart D, Klauss V, Baer F, et al. One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. JAm Coll Cardiol 2007;50:1627-34.
64. Lu Y-L, Chen Y, Lu S. Effects of antiplatelet therapy in patients with high platelet aggregability after percutaneous coronary intervention. Chin J Cardiovasc Dis 2007;35:793-6.
65. Menichelli M, Parma A, Pucci E, et al. Randomized trial of sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction (SESAMI). J Am Coll Cardiol 2007;49:1924-30.
66. Suh J, Kim WJ, Seo HS, et al. Clinical outcome of patients with diabetes mellitus and chronic total occlusion after drug-eluting stenting followed by cilostazol treatment. Eurointervention. 2009;5(Supp E)
67. Ardissino D, Cavallini C, Bramucci E, et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004;292:2727-34.
68. Menozzi A, Solinas E, Ortolani P, et al. Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study. Eur Heart J 2009;30:2095-101.
69. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
70. Lu YL, Chen YZ, Lv SZ, et al. Effect of cilostazol on restenosis in elderly patients with coronary bare-metal stents implantation. Chin J Geriatr 2006;25:537-78.